

20 **Abstract**

21

22 **Background:** Acute pancreatitis (AP) is a common clinical disease with varying severity. The
23 Revised Atlanta Classification (RAC) categorises AP into mild, moderately severe, and severe
24 (MAP, MSAP and SAP) respectively. Despite the availability of different scoring systems to
25 triage patients, these are not always suitable for predicting the course and outcome of certain
26 patients during admission. In this study, untargeted metabolomics was used to identify
27 metabolic parameters that can potentially be used as prognostic markers for stratifying the risk
28 profiles of patients for improved management and treatment.

29 **Methods:** Serum isolated from blood samples collected from 30 AP patients (8 MAP, 14
30 MSAP, and 8 SAP) and 9 healthy control (HC) individuals was analysed using ¹H nuclear
31 magnetic resonance (NMR) spectroscopy. Wilcoxon and Kruskal–Walli’s rank-sum tests were
32 used to compare differences in numerical covariates. A liposcale test was used for lipoprotein
33 characterization and the Spearman rank test was conducted for correlation of the data. P-values
34 < 0.05 were considered significant.

35 **Results:** Elevated levels of lactate, ($\rho = 0.67$; p-value < 0.001, FDR = 0.001), 3-
36 hydroxybutyrate ($\rho = 0.46$; p-value < 0.003, FDR = 0.013), acetoacetate ($\rho = 0.63$; p-value
37 < 0.001, FDR < 0.001) and lipid alpha-CH₂ ($\rho = 0.45$; p-value = 0.004, FDR = 0.013) were
38 associated with AP severity as was decreased levels of ascorbate ($\rho = 0.46$; p-value < 0.003,
39 FDR = 0.013), methanol ($\rho = 0.46$; p-value < 0.003, FDR = 0.013), glutamine ($\rho = -0.55$; p-
40 value < 0.001, FDR = 0.002), ethanol ($\rho = 0.64$; p-value < 0.001, FDR < 0.001), protein-NH
41 ($\rho = -0.75$; p-value < 0.001, FDR < 0.001) among others. HDL-C decreased while IDL-C and
42 VLDL-C increased across all the AP metabolic phenotypes compared to the HC.

43 **Conclusion:** Dysregulated metabolites and lipids can potentially add to the understanding of
44 the pathophysiological conditions of AP and can aid in the early prognosis and stratification of
45 patients for specialist care.

46 **Keywords:** Acute pancreatitis; Metabolites; Lipoproteins; Severity; Nuclear Magnetic
47 Resonance

48 **1) Introduction**

49 Acute Pancreatitis (AP) is an inflammatory condition resulting from the autodigestion of the
50 pancreas caused by the sudden release of digestive enzymes before they reach the small
51 intestine. AP clinically presents with nausea, vomiting, abdominal pain, and an increase in
52 amylase and/or lipase in the blood of patients, which is at least three times greater than the
53 normal range (Hofmeyr et al., 2014; Nadhem and Salh, 2017). Globally, the incidence of AP
54 ranges from 5 and 80 people per 100,000 population (Nesvaderani et al., 2015). The incidence
55 of AP in the Western world is well documented, except for Asia and Latin America (Iannuzzi
56 et al., 2022), and low- and middle-income countries such as South Africa, which have a
57 paucity of information (Anderson et al., 2008). Discovery studies from our setting have shown
58 changes in immunological molecules or lack thereof in various stages of the disease (Kay et
59 al., 2017; Thomson et al., 2018, 2019; Nalisa et al., 2021), but incidence studies are still
60 lacking. While there is currently no incidence study of AP in South Africa, hospital prevalence
61 studies have shown that there are increasing hospital admissions due to AP (Funnell et al.,
62 1993; John et al., 1997; Anderson et al., 2008). The most common aetiologies of AP worldwide
63 are biliary and alcohol induced (Zilio et al., 2019). Previously, alcohol-induced AP accounted
64 for most hospital admissions for pancreatitis while antiretroviral drugs (ARVs), endoscopic
65 retrograde cholangiopancreatography (ERCP), hypertriglyceridemia (HTG), or unknown
66 causes together contributed to 5% of the causes of this disease in South Africa (John et al.,
67 1997; Anderson et al., 2008). In 2021, Nalisa and colleagues demonstrated a changing
68 demography of AP aetiology with increasing biliary-related disease which was proportional
69 with alcohol-induced AP (Nalisa et al., 2021). Risk factors such as obesity, age, genetic
70 predisposition, and alcohol abuse differ according to the lifestyle of the population (Yadav and
71 Lowenfels, 2013; Nesvaderani et al., 2015) and play a big role in these changes. In China for
72 example, AP caused by HTG has surpassed alcohol-induced AP due to dietary habits (Yang and
73 McNabb-Baltar, 2020) and it will not be surprising if similar trends are reported in African
74 populations as more Western dietary habits are adopted. Black males have been reported to
75 have a very high risk of AP attributed to social factors such as excessive alcohol consumption
76 (Yang, 2008).

77

78 According to the Revised Atlanta Classification (RAC) of 2021, AP is categorized into three
79 classes namely mild AP (MAP), moderately severe AP (MSAP) and severe AP (SAP) (Banks
80 et al., 2013; Choi et al., 2017). The most common form is MAP, which is a self-limiting
81 disease, resolves within the first week or with minimum adverse effect. Moderately severe AP is
82 characterized by organ failure that is transient and resolves within 48 hours (Banks et al.,
83 2013). MSAP patients may develop local complications such as walled-off necrosis,

84 pseudocysts, pancreatic and peripancreatic necrosis, and pancreatic fluid collections (Afghani,
85 2014). Patients are diagnosed with SAP if organ failure persists for more than 48 hours after
86 admission and/or associated with pancreatic necrosis (Szatmary et al., 2022). Patients with AP
87 are at an increased risk of systemic inflammatory response syndrome (SIRS), due to the
88 activation of the immune system leading to complications such as organ failure and death
89 (Bruen et al., 2021). These patients present with local complications which persist due to the
90 compromised immune system and the resulting immune cascade increases the risk of mortality
91 by 30% (Banks et al., 2013; Yadav and Lowenfels, 2013). Therefore, the severity of the
92 inflammatory response in AP determines which patients will suffer organ failure and thus are
93 classified as severe cases or have a short self-limiting uncomplicated course, classified as
94 MAP.

95 AP has diverse presentations with clinical variations and an unpredictable course which makes
96 diagnosis and hence prognosis difficult due to changes in the threshold of blood enzymes such as
97 amylase and lipase (Treacy et al., 2001). The varying degrees of severity make it necessary for
98 patients to be evaluated on time in the emergency area for signs and symptoms which will aid in
99 the prevention of organ failure and/or death in patients during hospitalization. This is suggestive
100 of a tight therapeutic window, requiring swift responses, which involves monitoring,
101 intervention and supportive care which is ideally administered within the first 48-72 h from
102 disease onset (Gomatos et al., 2014). Although several rapid, cheap, and reliable tools have
103 been designed to assist clinicians to triage AP patients, sensitivity and specificity challenges
104 associated with the threshold change challenges with blood enzymes means prediction of the
105 disease severity and progression has not been easy and quick enough (Treacy et al., 2001;
106 Magrini et al., 2014; Gu and Tong, 2019; Silva-Vaz et al., 2020). Furthermore, the use of
107 computed tomography (CT) scan may be necessary in cases with diagnostic dilemma and/or
108 where determining the degree of necrosis, which is best demonstrable with imaging obtained
109 after 72 hours from the onset of AP is required (Leppäniemi et al., 2019). The use of these
110 techniques for the diagnosis of critically ill AP patients might delay treatment, which may result
111 in single or multiple organ failure and death, hence the need for more reliable and fast
112 alternatives.

113 Although, no effective medication exists for the treatment of AP, supportive care which is
114 dependent on the severity is applied (Banks et al., 2006). MSAP and SAP patients who require
115 specialized care are transferred to the intensive care unit (ICU). Antibiotics are administered to
116 patients with infected necrosis (Goodchild et al., 2019). In biliary-associated pancreatitis,
117 surgical interventions such as ERCP with early sphincterotomy can decrease the length of
118 hospital stay and complications (Quinlan, 2014; Chandrasekhara et al., 2017).

119 The initiation of AP causes alterations in biological processes due to the immune system being
120 activated in response to pancreatic injury (Zheng et al., 2013; Thomson et al., 2018; Nalisa et
121 al., 2021). The activated immune system affects metabolic processes by altering the blood
122 concentration of small molecules such as sugars, lipids, and amino acids (Gu and Tong, 2019;
123 Cacciatore et al., 2021; Elebo et al., 2021). The pancreas secretes digestive enzymes and
124 hormones, which play a key role in the regulation of metabolism, hence damage of pancreatic
125 cells as a result of AP affects the metabolome (Gu and Tong, 2019; Karpińska and Czauderna,
126 2022). This suggests that metabolomics of biofluids such as plasma and serum may be profiled to
127 retrieve information on the “health” status of the pancreas and pancreas-related diseases aiding in
128 the early detection, diagnosis and identification of novel biomarkers in pancreatic diseases (Gu
129 and Tong, 2019; Siddiqui et al., 2020). The earliest studies on the use of metabolomics to
130 determine metabolites in pancreatitis was the study by Bohus and colleagues and subsequently
131 various other studies have been conducted using different analytical techniques (Bohus et al.,
132 2008; Khan et al., 2013; Xu et al., 2016; Huang et al., 2019, 2022).

133 Nuclear magnetic resonance (NMR) spectroscopy is a technique used in metabolomics to
134 quantify a wide range of components, including low-molecular-weight metabolites, lipids, and
135 lipoproteins (Sakai et al., 2012; Cacciatore and Loda, 2015; Silva et al., 2020; Elebo et al.,
136 2021). The ^1H -NMR spectra allows resonances to be assigned directly to the metabolites based
137 on their chemical shifts, and signal multiplicities (Lindon and Nicholson, 2008). Several NMR
138 studies have shown that the integration of metabolites with meta-analysis of the transcriptome
139 revealed a pancreatitis background in pancreatic cancer, congruent with AP being a risk factor to
140 pancreatic cancer (Ketavarapu et al., 2022). Furthermore, ^1H -NMR metabolomics has been
141 used to distinguish between AP patients and healthy controls or those presenting with
142 abdominal pain (Luszczek et al., 2013; Villaseñor et al., 2014; Shah et al., 2023). In the study by
143 Villaseñor and colleagues in 2014, the authors found changes in the lipid profile with high
144 levels of low-density lipoprotein and unsaturated lipids, which are consistent with known
145 disruptions in lipid metabolism in AP. Most of these studies were carried out in other races and
146 population groups using urine and plasma samples and although the studies targeted metabolites
147 in AP, they did not associate them with severity and outcome. It is also notable that genetic and
148 environmental variations in immune and metabolic responses based on ethnicity means such
149 studies are important in our patient cohort (Yadav and Lowenfels, 2013; Nesvaderani et al.,
150 2015). Here, the serum metabolome of AP patients was profiled for the first time in an African
151 cohort using ^1H -NMR spectroscopy. This study aimed to investigate altered metabolites and
152 lipids to understand the underlying pathophysiological conditions of AP in the three AP
153 severities to enable improved prognosis, for early patient stratification and management.

154

155 **2 Materials and methods**

156

157 **2.1 Sample collection and processing**

158 Ethics clearance for this study was obtained from the Human Research Ethics Committee
159 (Medical) of the University of the Witwatersrand (Ethics No. M190407). The RAC of 2012
160 (MAP, MSAP, or SAP) was used by consulting clinicians to recruit participants at the Chris
161 Hani Baragwanath Academic Hospital (CHBAH). To be included in the study, participants had
162 to be 18 or more years old and self-identified as of African descent. Patients were excluded if
163 they had been diagnosed with auto-immune diseases, undergoing immunotherapy, and were on
164 antibiotics within one month of admission. Following informed consent from the participants,
165 blood samples were collected using red coloured non-anticoagulant BD vacutainer® blood
166 collection tubes (BD Biosciences, New Jersey, USA). Four millilitres (4mL) of blood was
167 drawn from eligible patients as previously described by Nalisa and colleagues on days 1, 3, 5,
168 and 7 post epigastric pain enabling time points and longitudinal analysis of the metabolic
169 changes (Nalisa et al., 2021). Patients typically reported to hospital on Day 3 of pain.

170

171 The clinical data were obtained from the patient's hospital files, via the National Health
172 Laboratory Services (NHLS) Trakcare Web Results, version L6.10, captured on the RedCap®
173 (Tennessee, USA) database. Captured data included demographic, body mass index (BMI), AP
174 aetiology, AP severity, clinical test results, and comorbidities. Healthy volunteers were
175 recruited as controls and were age and sex-matched with the AP patients. The collected blood
176 samples were allowed to stand upright for 30 minutes at room temperature in blood collection
177 tubes and then centrifuged at 1734 xg at 4°C for 30 minutes. The serum was aliquoted into
178 microfuge tubes of 500 μL volumes and stored at -80°C until needed for the analysis.

179 **2.2 Serum sample preparation**

180 The frozen serum samples, previously processed and stored at -80°C were left to thaw at room
181 temperature. A working solution was prepared by adding 300 μL of the thawed serum to 300 μL
182 of a solution consisting of 0.75 M potassium phosphate buffer (pH 7.4), 5.81 mM of
183 trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP; Sigma-Aldrich, St. Louis, MO, USA)
184 and a trace amount of sodium azide (65 mg dissolved in deuterium oxide) to prevent bacterial
185 growth. The samples were vortexed to obtain a homogenous mixture. A final volume of 540
186 μL of each sample was transferred to a 5 mm NMR tube (Wilmad Lab Glass, Vineland, NJ,
187 USA) for analysis.

188 **2.3 Lipid Extract Preparation**

189 The extraction of the lipids was performed using the protocol described by Lamiquiz-Moneo

190 and colleagues (Lamiquiz-Moneo et al., 2019). A volume of 300 μ L of BUME (butanol:
191 methanol—2:1) was added to 100 μ L serum aliquots in glass GC vials as well as 300 μ L DIPE
192 (diisopropyl ether: ethyl acetate—3:1) and 300 μ L H₂O. Firstly, BUME and H₂O were added
193 to the samples and vortexed for 1 minute. DIPE was then added to extract the lipids and the
194 mixture incubated on a shaker for 10 minutes. To separate the lipids from the mixture, the
195 samples were centrifuged at 2058 xg for 5 minutes. Afterwards, the top layer was transferred
196 to clean vials, dried under liquid nitrogen at 37 °C and then resuspended in 600 μ L solution of
197 CDC13:CD3OD:D₂O (chloroform-d:methanol-d:water-d; 16:7:1, v/v/v) containing 1.18 mM
198 TSP. A volume of 540 μ L of lipid extract samples were transferred to 5 mm NMR tubes
199 (Wilmad Lab Glass) and analysed using NMR spectroscopy.

200 **2.4 NMR Analysis**

201 The NMR tubes containing the diluted metabolite and lipid extracts, respectively were loaded
202 on a 500 MHz Bruker Avance III HD NMR spectrometer equipped with a triple- resonance
203 inverse 1H probe head and x,y,z gradient coils. Afterwards, one- dimensional (1D) proton
204 (1H)-NMR spectra were acquired using different pulse sequences. A standard nuclear
205 overhauser effect spectroscopy (NOESY) pulse sequence presat (noesygprr1d.comp) was used
206 on both the metabolite and lipid extract samples. NOESY was used to detect both signals of
207 small metabolites and high-molecular-weight macromolecules such as lipoproteins.
208 Additionally, a standard diffusion-edited (DIFF) pulse sequence (ledbgprr2s1d) was used to
209 detect only high- molecular-weight macromolecules, such as lipoproteins. Pooled AP samples
210 of different severities were used as a quality control sample and were included in each batch
211 for qualitative assessment of repeatability by overlaying the raw spectra.

212 **2.5 NMR Profiling**

213 NMR spectroscopy was used to quantify a panel of 38 signals. The peaks of the identified
214 metabolites were fitted by combining a local baseline and Voigt functions based on the
215 multiplicity of the NMR signal (Marshall et al., 1997). The assignment of quantified signals is
216 reported in **Table S1**. To validate the efficacy of the different deconvolution models, the root-
217 mean-square deviation was determined. The absolute concentration of each metabolite was
218 calculated according to a previously reported equation (Serkova et al., 2005). The number of
219 protons contributing to the unknown signals was imputed to 1. The concentration of
220 carbohydrates was also estimated by considering the equilibrium between their cyclic forms.

222 N-acetylglucosamine/galactosamine (GlycA) and N-acetylneuraminic acid (GlycB) signals
223 were quantified as inflammatory markers by integrating the areas between 2.00 and 2.05 ppm
224 and 2.09 and 2.05 ppm, respectively. GlycA is measured as an NMR signal of post-

225 translational modification of glycosylated acute-phase proteins released during inflammation
226 (Otvos et al., 2015). The Liposcale test (Biosfer TesLab, Reus, Spain) was then used to
227 determine lipoprotein parameters, high-density lipoprotein (HDL), low-density lipoprotein
228 (LDL), and very low-density lipoprotein (VLDL) particle number, size, and lipid concentration
229 of each subtype (Mallol et al., 2015), was used as previously described by (Elebo et al., 2021).
230 Each of the DIFF spectrum in the range between 0.1 and 9.5 ppm, excluding the regions
231 corresponding to the water signals between 4.40 and 5.00 ppm, was segmented into 0.001-ppm
232 chemical shift bins, and the corresponding spectral areas under the curve, giving a total of 8800
233 variables.

234 **2.6 Statistics and Data Analysis**

235
236 Statistical analysis and graphical illustrations of the data were generated in R (version 3.6.1)
237 and R studio (version 1.1.456) software using scripts developed in-house. Wilcoxon and
238 Kruskal-Wallis rank-sum tests were used to compare differences in numerical covariates (e.g.,
239 age and metabolite concentration). Fisher's exact test was used to assess differences between
240 categorical variables (e.g., gender), and Spearman's rank test was then used to calculate the
241 correlation coefficient (ρ) between variables. P-values < 0.05 were considered significant
242 and to account for multiple testing, a false discovery rate (FDR) of $< 10\%$ was applied.

243 The KODAMA algorithm, which allows for unsupervised extraction of features and enables
244 analysis of noisy datasets of high dimension was used to facilitate the identification of patterns
245 representing underlying metabolic phenotypes on all samples (Cacciatore et al., 2014, 2017;
246 Bray et al., 2017). The partition around medoids (PAM) clustering (Reynolds et al., 2006) was
247 applied to the KODAMA scores using the silhouette algorithm 10 (Rousseeuw, 1987) to verify
248 the results obtained. The silhouette median value was utilized to assess the ideal number of
249 clusters, ranging from 2 to 10.

250 Using partial least-squares (PLS) analysis, regression was performed on DIFF spectra metabolic
251 profiles. Furthermore, 10-fold cross-validation was performed to evaluate the predictive
252 efficacy of the model (Bertini et al., 2012). Both the goodness of fit parameter (R^2) and the
253 predictive ability parameter (Q^2) were also calculated using standard formulas (Eriksson et al.,
254 2003). The Q^2 value was calculated from the p-value to assess the performance of the PLS
255 regression model (Szymańska et al., 2012). A p-value < 0.05 was regarded as significant.

256 **3 Results**

257

258 **3.1 Demographics and Clinical Characteristics**

259

260 3.1.1 Patients' demographic and clinicopathological characteristics

261

262 Thirty (30) patients with AP (MAP = 8, MSAP = 14, and SAP = 8) met the inclusion criteria

263 and 9 healthy controls (HC) were all enrolled in the study. There were equal number of males
264 (11) and females (11). There were no statistically significant differences in BMI, age, and
265 gender across the four groups as shown in **Table 1**. The primary aetiology of AP in this study
266 was alcohol-induced (16/30 = 53%) occurring mostly in males (12/16=75%). Biliary
267 associated-AP was the second common aetiology (12/30 = 40%) with majority being female
268 (9/12=75%), and ARV-induced AP was 7% of the population (2/30) as shown in **Table S2**. In
269 this study, 50% of AP patients with ARV-associated aetiology were women.

270 The incidence of organ dysfunction (OD) increased with the severity of AP, with 50% of
271 MSAP patients having respiratory OD as shown in **Table 1**. Imaging findings consistent with
272 local complications, such as pancreatic collection and wall-off necrosis, were found in some
273 MSAP and SAP patients. As expected, admissions to the Intensive Care Unit (ICU) and
274 hospital death were prevalent in SAP patients.

275

276 3.1.2 Routine clinical / Biochemical tests

277 No statistically significant correlation was observed between the severity of AP and routine
278 biochemical tests such as amylase, lipase, CRP, haemoglobin, haematocrit and platelets (**Table**
279 **S3**). The median values of liver function parameters; total bilirubin, conjugated bilirubin,
280 alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP)
281 were observed to be elevated above the physiological range for SAP patients. A third (10/30) of
282 the patients in our cohort were affected by hypoalbuminemia, in contrast, no correlation with
283 severity was reported with CRP (**Figure 1A**). In this cohort, amylase and ALP ($p<0.001$)
284 showed statistically significantly higher concentrations in biliary-associated AP with their
285 combination able to differentiate biliary-associated from alcohol-associated AP as
286 demonstrated in **Figure 1B**.

287
288


Table 1: Demographic and clinical characteristics of the acute pancreatitis patients

Feature	Control (n=9)	MAP (N=8)	MSAP (N=14)	SAP (N=8)	p-value
BMI (kg/m ²), median [IQR]	30.4 [23.6 32.8]	24.8 [24.7 44.3]	27 [23.2 30.5]	32 [30.9 39.8]	0.515
Age (years), median [IQR]	43 [30 54]	43.5 [36.5 54.8]	38 [32 43.5]	48 [32.2 57.2]	0.613
Gender					0.100
F, n (%)	5 (55.6)	4 (50.0)	7 (50.0)	4 (50.0)	
M, n (%)	4 (44.4)	4 (50.0)	7 (50.0)	4 (50.0)	
Aetiology of pancreatitis					
Biliary, n (%)		4 (50.0)	5 (35.7)	3 (37.5)	
Alcohol, n (%)		4 (50.0)	8 (57.1)	4 (50.0)	
ARVs, n (%)		0 (0.0)	1 (7.1)	1 (12.5)	
Days of hospitalization, median [IQR]		10.5 [4.8 15]	9 [4.8 11]	8 [8 10]	0.864
no, n (%)		7 (87.5)	10 (71.4)	8 (100.0)	
yes, n (%)		1 (12.5)	4 (28.6)	0 (0.0)	
Diabetic					0.100
no, n (%)		8 (100.0)	13 (92.9)	8 (100.0)	
yes, n (%)		0 (0.0)	1 (7.1)	0 (0.0)	
HIV					0.650
no, n (%)		7 (87.5)	10 (71.4)	7 (87.5)	
yes, n (%)		1 (12.5)	4 (28.6)	1 (12.5)	
Organ dysfunction					0.027
no, n (%)		8 (100.0)	8 (57.1)	3 (37.5)	
renal, n (%)		0 (0.0)	0 (0.0)	1 (12.5)	
respiratory, n (%)		0 (0.0)	3 (21.4)	4 (50.0)	
transient renal, n (%)		0 (0.0)	3 (21.4)	0 (0.0)	
Local Complications					0.878
ANP, n (%)		1 (12.5)	0 (0.0)	0 (0.0)	
no, n (%)		7 (87.5)	10 (76.9)	6 (85.7)	
pancreatic collection, n (%)		0 (0.0)	1 (7.7)	0 (0.0)	
peripancreatic fatty stranding, n (%)		0 (0.0)	0 (0.0)	1 (14.3)	
wall off necrosis; ANC, n (%)		0 (0.0)	1 (7.7)	0 (0.0)	
yes, but not reported, n (%)		0 (0.0)	1 (7.7)	0 (0.0)	
Admission to ICU					0.004
no, n (%)		8 (100.0)	13 (92.9)	3 (37.5)	
yes, n (%)		0 (0.0)	1 (7.1)	5 (62.5)	
Surgical procedures					0.566
cholecystectomy, n (%)		2 (28.6)	1 (7.7)	0 (0.0)	
ERCP, n (%)		0 (0.0)	1 (7.7)	1 (14.3)	
None, n (%)		5 (71.4)	11 (84.6)	6 (85.7)	
Hospital death					0.02
no, n (%)		8 (100.0)	13 (92.9)	4 (50.0)	
yes, n (%)		0 (0.0)	1 (7.1)	4 (50.0)	

289
290
291

Abbreviations. ARVs- antiretrovirals, HIV- human immunodeficiency virus, ANP- Atrial natriuretic peptide, ANC- absolute neutrophil count, ICU- intensive care unit, ERCP Endoscopic retrograde cholangiopancreatography, IQR- The Interquartile Range.

292 Most AP patients in this cohort showed a very high values of CRP (>10 mg/L). AP patients
 293 with CRP higher than 150 mg/L and albumin lower than 35 g/L were more likely to experience
 294 in-hospital death or have organ dysfunction (11/13=85%). A comparison of the biochemical
 295 tests showed that both amylase (p -value <0.001; FDR= 0.008) and ALP (p -value <0.001; FDR=
 296 0.003) were statistically different among the 3 different aetiologies of AP (**Table S4**). The
 297 Glasgow Prognostic Score (GPS) reflects the systemic inflammatory response, derived from
 298 the serum concentrations of CRP, and nutritional status, derived from the albumin levels
 299 (Forrest et al., 2003). This score ranges from 0 to 2 with a higher value implying the presence
 300 of both abnormalities high CRP and low albumin levels. Based on our reported CRP and
 301 albumin levels, 32% (7/22) of AP patients had a GPS of 2, while 64% (14/22) AP patients had
 302 a GPS score of 1 and 4% of patients had a GPS of 0. Furthermore, there were no statistically
 303 significant differences observed for a comparative analysis between the different AP severity
 304 groups and biochemical tests performed in biliary-associated AP (**Table S5**) and alcohol-
 305 associated AP (**Table S6**).



306

307 **Figure 1.** Plot showing (A) correlation between albumin and CRP: The top and middle right quadrants are patients with Glasgow Prognostic
 308 Score (GPS) =1 with CRP> 150mg/L and albumin levels > 35g/L while the left quadrants are patients with GPS =2. Although the top right
 309 quadrant has GPS=1, the patients are characterised with an elevated organ dysfunction levels and (B) the correlation between amylase and
 310 ALP: Decreased levels of both amylases and alkaline phosphatase (ALP) is associated with alcohol-associated AP while the increased levels
 311 are linked to biliary-associated AP. GPS of 0, 1 or 2 refers to neither, one or both abnormalities.
 312
 313

314 3.2 Metabolites and acute pancreatitis severity

315

316 NMR spectroscopy was used to profile the concentration of metabolites and lipids and in total
 317 38 metabolic signals, including lipid classes and the NMR inflammatory markers, GlycA and
 318 GlycB, were reported. To delineate the metabolic signatures of AP, the Spearman correlation
 319 test was performed to link metabolic parameters to the different groups in the following rank
 320 order: HC=0, MAP =1, MSAP =2, and SAP = 3 (**Table 2**). Elevated levels of 3-
 321 hydroxybutyrate (3-HB), acetoacetate, phenylalanine, mannose, and lactate, as well as
 322 decreased concentrations of ascorbate, methanol, ethanol, and glutamine was observed with
 323 increased AP severity. Additionally, AP severity showed a large alteration in lipid profile with
 324 increases lipid alpha-CH₂ and decreases in cholesterol, Lipid=CH-CH₂-CH=, Lipid beta-CH₂
 325 and lipid CH₃ respectively with diseases severity as well as a depletion of the serum levels of
 326 protein

327 (Protein NH). Furthermore, three unknown signals; 1.45, 1.11 and 1.06 ppm were observed to
 328 be statistically significant. Although not statistically significant, inflammatory markers GlycA
 329 and GlycB showed a positive correlation with the severity of the disease. The aetiology of AP,
 330 i.e., alcohol or biliary-induced, did not have a significant impact on the metabolic profile
 331 (Table S7).

332

333 **Table 2** Correlation of concentrations of metabolites with the severity of acute pancreatitis

334

Feature	rho	p-value	FDR
Formate	0.04	0.793	0.809
Unknown signal at 8.12 ppm	0.01	0.951	0.951
Unknown signal at 8.07 ppm	-0.08	0.630	0.684
Phenylalanine	0.54	<0.001	0.028
Tyrosine	-0.13	0.443	0.525
Unknown signal at 7.14 ppm	0.19	0.237	0.318
Histidine	-0.1	0.557	0.631
Glucose	0.24	0.140	0.238
Mannose	0.57	<0.001	0.015
Unknown signal at 5.15 ppm	0.23	0.155	0.239
Unknown signal at 5.09 ppm	0.16	0.330	0.421
Unknown signal at 5.01 ppm	0.23	0.155	0.239
Ascorbate	-0.46	0.003	0.013
Threonine	-0.33	0.043	0.104
Lactate	0.67	<0.001	<0.001
Creatinine	0.2	0.218	0.309
Creatine	0.3	0.064	0.143
Glycine	0.06	0.717	0.746
Methanol	-0.46	0.001	0.013
Unknown signal at 2.55 ppm	0.25	0.130	0.229
Citrate	-0.16	0.330	0.421
Glutamine	-0.55	<0.001	0.003
Pyruvate	0.2	0.230	0.317
Glutamate	0.25	0.126	0.229
Acetoacetate	0.63	<0.001	<0.001
Acetate	0.28	0.089	0.169
Alanine	-0.29	0.077	0.158
Unknown signal at 1.45 ppm	0.44	0.005	0.016
Unknown signal at 1.43 ppm	0.23	0.155	0.239
3-Hydroxybutyrate	0.46	<0.001	0.013
Ethanol	-0.64	<0.001	<0.001
Unknown signal at 1.16 ppm	-0.07	0.686	0.729
Unknown signal at 1.14 ppm	0.31	0.054	0.124
Unknown signal at 1.11 ppm	0.47	0.003	0.013
Unknown signal at 1.06 ppm	0.4	0.011	0.032
Valine	-0.14	0.411	0.511
Isoleucine	0.22	0.018	0.276
Leucine	0.11	0.049	0.564
2-Hydroxybutyrate	0.34	0.032	0.081
Protein NH	-0.75	<0.001	<0.001
Unsaturated lipid -CH=CH-	-0.35	0.029	0.077
Lipid alpha-CH2	0.45	0.004	0.013
Cholesterol	-0.43	0.006	0.017
Lipid =CH-CH2-CH=	-0.55	<0.001	0.002
Glycerol phospholipid	0.21	0.199	0.289
Phospholipid	-0.13	0.440	0.525
Lipid beta-CH2	-0.52	<0.001	0.004
Lipid CH2	0.09	0.599	0.664
Lipid CH3	-0.44	0.005	0.016
GlycB	0.28	0.085	0.167
GlycA	0.29	0.074	0.158

Rho: Spearman's correlation coefficient; FDR: False Discovery rate

335 **3.3 The Relationship between the metabolic phenotype and clinical outcomes of acute** 336 **pancreatitis**

337 Unsupervised KODAMA analysis was performed to visualize patterns between metabolic
338 phenotypes (metabotype) and disease severity as described in **Figure 2A**. This operation
339 separated the patient cohort into three different metabotypes. A distinct metabolic profile was
340 observed for the healthy controls compared to AP patients. Notably, a clear separation was
341 also evident between patients with MAP and SAP. Interestingly, two patients with SAP
342 showed a metabolic profile similar to the MAP. Further analysis indicated that these patients
343 had elevated levels of free cholesterol/cholesterol ester ratio, which could be due to cholestasis
344 linked to lipoprotein X (LpX). Cholestasis is characterized by the presence of Lpx (Brandt et
345 al., 2015; Phatlhane and Zemlin, 2016), that could mask the SAP phenotype. The group of AP
346 patients with intermediate severity (i.e., MSAP) shared metabolic profiles with both MAP and
347 SAP patients (**Figure 2B**). However, MSAP patients with a closer phenotype to SAP had a
348 higher incidence of adverse events (**Figure 2C**). Some of the adverse events were complications
349 such as infection and pseudocysts, organ dysfunction (OD), and admission to the ICU.
350 Notably, increases in lactate activity, shown by the colour changes from blue through yellow
351 in the heatmap (**Figure 2D**), which is prevalent in the SAP patients also corresponds with
352 increase OD, local complications, ICU admission and death.

353 A further comparison of the clinical features and the metabolite profile showed that the lipid
354 profile distinctively separated the metabolic phenotypes of AP based on their severity with an
355 overall decrease in lipid levels with increasing AP severity (**Figure 2D**). The concentration of
356 high-density lipoprotein particles (HDL-P) seemed to constitute the difference in the
357 dyslipidaemia found between the metabolic phenotypes, with a notable decrease with
358 increasing AP severity (**Figure 2E**). The inflammatory marker, GlycA, increased across the
359 group and was highest in the MSAP patients (**Figure 2F**). After further characterisation of
360 cholesterol-related lipids, it was shown that dysregulation of HDL (decreasing with severity)
361 and IDL and VLDL (both increasing with severity), were linked to AP severity (**Figure 2G**).




Figure 2: Overview of the metabolic phenotypes of AP and their effects. **A**; Unsupervised analysis of the metabolites of HC (n = 9), MAP (n = 8), MSAP (n = 14), and SAP (n = 8). Two distinct clusters representing the metabolic phenotype of mild and severe AP separated with most of the MAP and about 5 of the MSAP in the first component while most of the SAP except for 2 patients are in the second component (components are delineated throughout relevant figures using broken vertical lines). **B**; The distribution of the different AP and HC groups, the distinct separation of the HC and SAP was observed at the left and right of the graph respectively. Both MAP and MSAP were observed in the middle with MAP at the left end and the MSAP at the right end. **C**; Comparison of the incidence of the clinical features across the groups. MAP had the least adverse effect and complications while SAP presented the most adverse effects including death. MSAP had the highest levels of organ dysfunction and complication in hospitalized patients. **D**; Heatmap showing the comparison of the clinical features and the metabolites across the AP groups. Lipid profiles were observed to distinctly separate the AP groups as colour changes were observed from blue to red. **E** and **F**; small HDL-P and GlycA across the metabolic phenotypes of AP. Decreased levels of small HDL-P with increased AP severity were observed. GlycA increased for the mild pancreatic phenotype and reflects a moderated decline for the severe phenotype. **G**; Distribution of cholesterol related lipids across the various components from HC, MAP/MSAP and MSAP/SAP. HDL-C decreased from HC to SAP while both VLDL-C and IDL-C were elevated. Decreased HDL-C in AP might represent impaired anti-inflammatory function, reduced lipoprotein synthesis, and impaired immune functions.

HDL- High-density lipoprotein, HDL-P- HDL-Particle, LDL- Low-density lipoprotein, VLDL-Very-Low Density Lipoprotein, IDL - immediate-density lipoprotein.

362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378

379 3.4 Trend Analysis

380 To further understand the association of metabolites and lipoproteins with AP severity,
381 KODAMA analysis was used to analyse three representative molecules (GlycA, 3-
382 hydroxybutyrate and lipid alpha-CH2). A comparison of the metabolites (**Table S8**) and
383 lipoproteins (**Table S9**) with inverted first dimension KODAMA showed dysregulated
384 metabolites such as mannose, ascorbate, phenylalanine and lipoproteins among others as we
385 move from MAP to SAP. Some of these metabolites were also dysregulated over time as days
386 progressed from days 1 – 7 for selected severities albeit inconsistently for example 3-
387 hydroxybutyrate in SAP patients. The correlation of the concentration of metabolites with AP
388 severity showed that GlycA (p- value = 0.004) for example, was significantly altered (**Figure**
389 **3A, Table S10**). In this pilot study, the ketoacidosis metabolite, 3-hydroxybutyrate (p-value =
390 0.003) was shown to be significantly linked to worse clinical outcomes in AP as shown in
391 **Figure 3B (Table S11)** and within the severe group this seems to increase with time from day1
392 to day 7. Elevated levels of 3-hydroxybutyrate were observed in SAP patients compared to the
393 other severity groups. A metabolite of interest, Lipid alpha-CH2 was observed to be
394 dysregulated in AP patients with organ dysfunction (**Figure 3C**). Elevated levels of alpha-CH2
395 (p-value = 0.007) were seen in SAP compared to MSAP and MAP (**Table S12**). Within
396 patients, it appeared to be consistent over time.




Figure 3: Trends in selected metabolic parameters. A; describes the pattern for GlycA in the severity groups of AP over all time points. B; assess levels of 3-hydroxybutyrate in the severity groups of AP over all time points. C; describes the pattern for lipid alpha-CH2 in the severity groups of AP over all time points.

4 Discussion

In this preliminary study, the demographics, clinicopathological characteristics, as well as the metabolite and lipoprotein profiles of 30 AP patients were analysed to assess the relationship of these parameters to AP severity and clinical outcome. Importantly, the identification of a metabolotype that could help in prognosticating AP disease severity was envisaged.

Approximately 57% (17/30) of the AP patients were obese with a BMI of 32 kg/m² and a median IQR of 30.9 - 39.8 kg/m² in SAP. Notably, obesity was more common in patients with biliary-associated AP. An increase in BMI of about 83% (10/12) was observed for the biliary-associated AP. Previous studies have shown that comorbidities such as obesity affect the clinical outcomes of AP (Khatua et al., 2017; Moran et al., 2018), and this is also true for the cohort evaluated.

Of interest, this study showed that alcohol-induced AP is the main aetiology of male AP patients while biliary associated AP is common in females. On the contrary, a retrospective study in a Western society showed biliary-induced AP, which is prevalent in females, to be the main cause of AP followed by alcohol, which was predominantly in males (Nesvaderani et al., 2015). Furthermore, over 50% of the female AP patients in this study were living with HIV/AIDS and on

421 antiretroviral therapy (ART). Acute pancreatitis is extremely high in people living with HIV/AIDS
422 (PLWHA), which could be due to the long-term use of antiretroviral therapy (ART) medications
423 such as corticosteroids and sulphonamides (Dragovic, 2013). Importantly, the aetiology of AP did
424 not have a notable impact on the metabolic profile as shown in Table S7, and this might be because
425 the course of the disease is not usually affected by the aetiology (Fonteh et al., 2018).

426 Serum amylase and lipase are routine tests used for the diagnosis of AP (Ismail and Bhayana,
427 2017). According to the South African NHLS report, the physiological concentrations of amylase
428 and lipase range from 28 -110 U/L and 13 - 60 U/L respectively (National Health Laboratory
429 Services 2019/20 Annual Report; National Health Amendment Bill: rejection | PMG, n.d.). Our
430 study participants had higher concentrations of both amylase and lipase, about three times above
431 the normal limit but no statistically significant differences were found between the groups
432 probably because of the small sample sizes. Elevated levels of amylases and ALP were observed
433 in our study population, which suggests liver damage or a blocked bile duct in biliary pancreatitis
434 (Fratantoni et al., 2021) hence these findings could be vital in distinguishing from alcohol-induced
435 AP (Hong et al., 2017). Indeed, this study confirms that the combination of amylase and ALP can
436 be used to differentiate biliary-associated AP from alcohol-associated AP (Güngör et al., 2011;
437 Thiagarajan and Amirthavarshini Ponnuswamy, 2020).

438 This study further confirms the previously reported direct association of hypoalbuminemia with
439 severity and mortality in AP (Ocskay et al., 2021). Elevated inflammatory states have been shown
440 to decrease albumin levels via capillary leak or induction of shorter half-life associated with
441 increased severity (Soeters et al., 2019; Ocskay et al., 2021). In contrast, there was no correlation
442 reported between CRP and severity in AP in this cohort. This is not surprising given that there is
443 conflicting evidence in the literature on the role of CRP in discriminating complicated AP early in
444 the disease (Ahmad et al., 2021). Rather, CRP is considered useful in predicting severity when
445 used in combination with other scoring systems to differentiate mild from severe patients for early
446 decision making. Most AP patients in this cohort showed high values of CRP (>10 mg/L). Based on
447 these values, we further analysed the patients for systemic inflammation and nutritional status
448 using the GPS system. The data showed that 32% (7/22) of AP patients were classified with a GPS
449 of 2, 64% (14/22) with a GPS of 1; only 4% of patients were classified with a GPS of 0. From the
450 results, MSAP patients had the most complications and organ failure from pancreatic necrosis,
451 which ultimately results in organ failure if unresolved (Niknam et al., 2020). SAP had the most
452 number of deaths, which is unsurprising given that SAP is characterized by persistent organ failure
453 for over 48 hours (Foster et al., 2016). Most of these SAP patients also generally had higher CRP
454 levels and hypoalbuminemia. The disease progression leading to organ failure and/or death in AP

455 is usually due to SIRS, which is a response to an infection or an injury in the pancreas (Garg and
456 Singh, 2019).

457 In this study, the physiological metabolite created was able to distinguish between the mild and
458 the severe groups of patients. AP patients undergo a hypermetabolic condition, which dysregulates
459 amino acid, lipid, and glucose metabolism (Kotan et al., 2023). Metabolites such as lactate,
460 phenylalanine, mannose, and acetoacetate, and 3-HB increased in concentration while ascorbate,
461 methanol, ethanol, and glutamine reduced with AP severity in this cohort. Similar findings have
462 been reported by Li *et al.*, (2014) and Xiao *et al.*, (2017) in various AP settings (Li et al., 2014;
463 Xiao et al., 2017).

464 Lactate levels were the most positively correlated metabolite with AP severity. Oxygen deficiency
465 and increased energy consumption enhances anaerobic glycolysis, which occurs in the early phase
466 of AP ultimately leading to elevated levels of lactate, a glycolytic metabolite (Li et al., 2014).
467 Increased lactate concentration has been associated with persistent organ failure in AP (Valverde-
468 López et al., 2017) and is independently associated with poor outcomes and death (McDonald et
469 al., 2017). Increases in mannose levels also positively correlated with AP severity and are not
470 surprising given the involvement of the glycolytic pathway (Xiao et al., 2017).

471 Organ failure and mortality have been associated with raised phenylalanine levels in the plasma of
472 AP patients (Chen et al., 2020; Xu et al., 2020). Increases in phenylalanine levels could be as result
473 of scavenging of tetrahydrobiopterin, a key co- factor involved in the conversion of phenylalanine to
474 tyrosine (Sandstrom et al., 2008). Dysregulated amino acid metabolism leads to the release of
475 excess acetyl CoA into the tricarboxylic acid (TCA) cycle, which is converted to ketone bodies
476 such as 3-HB (Li et al., 2014). Ketones, which are products of the oxidative pathway of alcohol
477 metabolites could be predictive of alcohol-induced AP (McGuire, 2006; Villaseñor et al., 2014).
478 Elevated levels of 3-HB in AP has been shown to differentiate between MAP and SAP (Xiao et al.,
479 2017) and associated with poor survival rates in pancreatic cancer (Elebo et al., 2021). In this
480 study, the 3-HB increased with severity and was found to persist in the SAP patients over time
481 when a trend analysis was performed. Hydroxybutyrate dehydrogenase enzyme, which catalyses
482 the breakdown of 3-HB to acetoacetate, another ketone (Hoque et al., 2009), has been shown to
483 significantly increase with organ failure and SIRS (Xiao et al., 2020). The increasing levels of both
484 3-HB and acetoacetate with increasing severity is suggestive of the reversible reaction between the
485 two molecules with the possibility of an equilibrium. Hence, both 3-HB and acetoacetate could be
486 used as a clinical biomarker to predict worse outcomes.

487 It is not surprising that ascorbate (vitamin C) levels decreased in this study with increasing AP
488 severity, a phenomenon that has been previously reported (Gao et al., 2021). Due to this deficiency

489 in ascorbate in AP, high doses of ascorbate have shown therapeutic efficacy in AP (Du et al.,
490 2003). Glutamine levels also significantly decreased with increasing AP severity. The consumption
491 of glutamine by immune cells is similar if not more than that of glucose and it is essential for
492 processes such as the proliferation of immune cells and the production of cytokines amongst others
493 (Cruzat et al., 2018). (The inflammatory and immune compromised patient, therefore, inevitably
494 experiences decreasing levels with severity as was the case here.

495
496 The level of two alcohols, methanol and ethanol, decreased with increasing AP severity but just like
497 the rest of the metabolites, were not significantly different between biliary and alcohol induced AP
498 patients (**Table S7**) as would have been expected. This lack of a strong metabolic signature is
499 supported by the fact that irrespective of the cause of AP, the trajectory is usually the same
500 (Fonteh et al., 2018), hence aetiology does not influence metabolite. In addition, the mechanisms
501 underlying the aetiology of AP have not been extensively elucidated especially for alcohol-
502 induced AP and could potentially shed light on this. This study showed a dyslipidaemic profile
503 with AP groups distinctly based on their severity. Serum lipid levels are associated with the
504 severity of acute pancreatitis (Khan et al., 2013; Zhang et al., 2017). Small HDL-P decreased with
505 increased severity of AP. Studies have shown that small HDL-P played a vital role in the ATP
506 binding Cassette transporter A 1 (ABCA-1) mediated cholesterol efflux from macrophages, which
507 leads to the deployment of intracellular cholesterol to the plasma membrane (Du et al., 2015).
508 HDL-C decreased from HC to SAP while IDL and VLDL increased with severity. Recent studies
509 demonstrated that decreased HDL- C levels are an independent prognostic factor of adverse
510 outcomes such as persistent organ failure and death (Zhang et al., 2017). HDL-C possesses anti-
511 inflammatory properties, hence decreased amounts could be latent for AP severity (Murphy and
512 Woollard, 2010). Oxidized VLDL is a marker of oxidative stress which inhibits lipoprotein lipase
513 responsible for triglyceride (TG) metabolism (Jong et al., 2000). Elevated VLDL levels are
514 associated with HTG which is the third leading cause of AP and correlates with increased severity
515 (Yang and McNabb-Baltar, 2020), raising the question whether there could be HTG associated AP
516 in the study setting. Protein concentration decreased with increased severity in this study
517 confirming that AP promotes protein catabolism, which involves the breakdown of proteins into
518 amino acids (Singh et al., 2012). Hence, the presence of pancreatic inflammation could lead to an
519 alteration in the level of metabolites (Xiao et al., 2017).

520 This study confirms that inflammation plays a vital role in AP severity (Iyer et al., 2020). AP patients
521 with CRP > 150 mg/L and Albumin < 35 g/L were more likely to die in- hospital or have organ
522 dysfunction. Furthermore, GlycA was most elevated in MSAP with a slight increase in the SAP
523 patients, suggesting increased inflammation levels in MSAP compared to MAP and SAP. Although

524 the differences in GlycA between the groups in this study were not significantly different, it is
525 notable that in a recent study, Shah and colleagues show that GlycA could be used as a novel
526 diagnostic marker of inflammation in AP when compared to healthy controls (Shah et al., 2023).
527 Increases in GlycA and GlycB have been shown in other acute phase inflammatory diseases such as
528 COVID-19 (Holmes et al., 2021; Lodge et al., 2021). Here, we show that GlycA could be targeted
529 as a biomarkers of inflammation in AP.

530 The transcription factor, NF- κ B, has been shown to promote the expression of genes involved in
531 inflammation, which are vital in various AP stages (Rakonczay et al., 2008). AP is an immune
532 disorder characterized by the release of either anti or proinflammatory cytokines (Zhang et al.,
533 2017). The impaired anti-inflammatory function might be linked to reduced HDL-C levels in AP
534 leading to increased free fatty acids (FFAs), which produce an acidic microenvironment (Zhang et
535 al., 2017). HDL-C also possesses an antioxidant ability, which is mediated by the paraoxonase-1
536 activity in AP (Yuksekdag et al., 2019). Notably, the presence of FFAs results from the breakdown
537 of TG including chylomicrons and is associated with HTG AP. The TGs are inherently not toxic but
538 the resultant lipotoxicity from the FFAs causes the release of intracellular calcium resulting in acinar
539 cell injury (Yang and McNabb-Baltar, 2020).

540 *Study limitations*

541 “Sick” control samples of patients presenting with other inflammatory diseases that could result in
542 the production of similar metabolites or lipoprotein profiles were not included in this study, hence
543 the specificity of the metabolic changes could not be fully ascertained. However, given that
544 metabolites in different diseases could be different due to differences in the disease course,
545 metabolomics testing stands to differentiate these markers due to the differing specificities and the
546 associated time bound nature (Gu and Tong, 2019). This study is a pilot study with small samples
547 sizes (30 AP patients), but comparatively, similar to other high profile published work and
548 findings.

549 **Conclusion:** This study provides crucial information for subsequent validation studies on a larger
550 cohort. These preliminary findings point to the possibility of using metabolites and lipoproteins in
551 delineating AP severity which adds value in understanding the pathophysiological conditions of
552 this disease, hence ultimately leading to early diagnosis and better care.

553 **Conflict of interest**

554 The authors declare that the research was conducted in the absence of any commercial or financial
555 relationships that could be construed as a potential conflict of interest.

558 **Author contributions**

560 JM: Sample acquisition/processing, analysis, interpretation, writing-original draft, writing- review
561 and editing. NE: formal analysis, interpretation, writing-original draft, writing-review and editing.
562 AW: design/methodology, formal analysis, interpretation, writing-review and editing. OM: clinical
563 data acquisition, formal analysis, interpretation, writing-review and editing. JD: clinical data
564 acquisition, interpretation, writing-review and editing, MD: clinical data analysis, interpretation,
565 writing-review and editing. SC: contributed analytical tools, methodology data analysis,
566 interpretation, writing-review and editing. PF: conceptualisation, obtained funding, formal analysis
567 and interpretation, project administration, supervision, writing-review and editing. All authors
568 approved the final version.

569

570 **Funding**

571 This study was supported by the South African National Research Foundation Grant 121277 and
572 the University of the Witwatersrand Faculty Research Committee Individual Grant
573 001254844110151211055254.

574

575 **Acknowledgements**

576

577 The patients, clinical staff, and clerks at Chris Hani Baragwanath Academic Hospital,
578 Hepatopancreatobiliary Unit and the Department of Surgery of the University of the
579 Witwatersrand are acknowledged. The Human Metabolomics Centre at the North-West University
580 for NMR Spectroscopy studies.

581

582 **Supplementary material**

583

584 **Tables S1-S10** where **Table S1** is the table of quantified signals and their relative assignment and
585 multiplicity; **Table S2** is the Aetiology and clinical characteristics of the AP patients, **Table S3:**
586 Clinical tests of patients with acute pancreatitis of different severity groups; **Table S4.** Comparison
587 of biochemical tests for the different aetiologies of acute pancreatitis; **Table S5.** Clinical tests of
588 patients with acute pancreatitis with biliary aetiology. All values are represented as median; **Table**
589 **S6:** Clinical tests of patients with alcohol-induced AP, values are represented as median; **Table**
590 **S7:** Comparison of metabolites with different aetiology groups of Acute Pancreatitis; **Table S8:**
591 Correlation of metabolites with inverted first dimension of KODAMA. Significantly dysregulated
592 metabolites and lipids; **Table S9:** Spearman correlation between lipoprotein parameters and
593 inverted first dimension of KODAMA and **Table S10:** Comparison of Metabolites and lipids with
594 severity in Acute Pancreatitis.

595 **Data availability statement**

596 All data produced in the present study are available upon reasonable request to the authors.

597

598 **References**

599

600 Afghani, E. (2014). Introduction to Pancreatic Disease: Acute Pancreatitis. *Pancreapedia Exocrine*
601 *Pancreas Knowl. Base*. doi: 10.3998/panc.2014.14.

602 Ahmad, R., Bhatti, K. M., Ahmed, M., Malik, K. A., Rehman, S., Abdulgader, A., et al. (2021). C-
603 Reactive Protein as a Predictor of Complicated Acute Pancreatitis: Reality or a Myth?
604 *Cureus*. doi: 10.7759/cureus.19265.

605 Anderson, F., Thomson, S. R., Clarke, D. L., and Loots, E. (2008). Acute pancreatitis□:
606 demographics, aetiological factors and outcomes in a regional hospital in South Africa□:
607 general surgery. *S. Afr. J. Surg.* 46, 83–86. doi: 10.10520/EJC66759.

608 Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., et al. (2013).
609 Classification of acute pancreatitis—2012: revision of the Atlanta classification and
610 definitions by international consensus. *Gut* 62, 102–111. doi: 10.1136/gutjnl-2012-302779.

611 Banks, P. A., Freeman, M. L., and Gastroenterology, P. P. C. of the A. C. of (2006). Practice
612 Guidelines in Acute Pancreatitis. *Off. J. Am. Coll. Gastroenterol. ACG* 101, 2379.

613 Bertini, I., Cacciatore, S., Jensen, B. V., Schou, J. V., Johansen, J. S., Kruhøffer, M., et al. (2012).
614 Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic
615 Colorectal Cancer. *Cancer Res.* 72, 356–364. doi: 10.1158/0008-5472.CAN-11-1543.

616 Bohus, E., Coen, M., Keun, H. C., Ebbels, T. M. D., Beckonert, O., Lindon, J. C., et al. (2008).
617 Temporal Metabonomic Modeling of L-Arginine-Induced Exocrine Pancreatitis. *J. Proteome*
618 *Res.* 7, 4435–4445. doi: 10.1021/pr800407j.

619 Brandt, E. J., Regnier, S. M., Leung, E. K., Chou, S. H., Baron, B. W., Te, H. S., et al. (2015).
620 Management of lipoprotein X and its complications in a patient with primary sclerosing
621 cholangitis. *Clin. Lipidol.* 10, 305–312. doi: 10.2217/clp.15.23.

622 Bray, R., Cacciatore, S., Jimenez, B., Cartwright, R., Digesu, A., Fernando, R., et al. (2017).
623 Urinary metabolic phenotyping of women with lower urinary tract symptoms. *4216*. doi:
624 10.1021/acs.jproteome.7b00568.

625 Bruen, C., Miller, J., Wilburn, J., Mackey, C., Bollen, T. L., Stauderman, K., et al. (2021). Auxora for
626 the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic
627 Inflammatory Response Syndrome. *Pancreas* 50, 537–543. doi:
628 10.1097/MPA.0000000000001793.

629 Cacciatore, S., and Loda, M. (2015). Innovation in metabolomics to improve personalized
630 healthcare. *Ann. N. Y. Acad. Sci.* 1346, 57–62. doi: 10.1111/nyas.12775.

631 Cacciatore, S., Luchinat, C., and Tenori, L. (2014). Knowledge discovery by accuracy
632 maximization. *Proc. Natl. Acad. Sci.* 111, 5117–5122. doi: 10.1073/pnas.1220873111.

633 Cacciatore, S., Tenori, L., Luchinat, C., Bennett, P. R., and MacIntyre, D. A. (2017). KODAMA: an
634 R package for knowledge discovery and data mining. *Bioinformatics* 33, 621–623. doi:
635 10.1093/bioinformatics/btw705.

636 Cacciatore, S., Wium, M., Licari, C., Ajayi-Smith, A., Masieri, L., Anderson, C., et al. (2021).
637 Inflammatory metabolic profile of South African patients with prostate cancer. *Cancer*
638 *Metab.* 9, 29. doi: 10.1186/s40170-021-00265-6.

639 Chandrasekhara, V., Khashab, M. A., Muthusamy, V. R., Acosta, R. D., Agrawal, D., Bruining, D.
640 H., et al. (2017). Adverse events associated with ERCP. *Gastrointest. Endosc.* 85, 32–47.

- 641 doi: 10.1016/j.gie.2016.06.051.
- 642 Chen, W.-S., Wang, C.-H., Cheng, C.-W., Liu, M.-H., Chu, C.-M., Wu, H.-P., et al. (2020). Elevated
643 plasma phenylalanine predicts mortality in critical patients with heart failure. *ESC Heart*
644 *Fail.* 7, 2884–2893. doi: 10.1002/ehf2.12896.
- 645 Choi, J.-H., Kim, M.-H., Cho, D. H., Oh, D., Lee, H. W., Song, T. J., et al. (2017). Revised Atlanta
646 classification and determinant-based classification: Which one better at stratifying
647 outcomes of patients with acute pancreatitis? *Pancreatology* 17, 194–200. doi:
648 10.1016/j.pan.2017.01.004.
- 649 Cruzat, V., Macedo Rogero, M., Noel Keane, K., Curi, R., and Newsholme, P. (2018). Glutamine:
650 Metabolism and Immune Function, Supplementation and Clinical Translation. *Nutrients* 10,
651 1564. doi: 10.3390/nu10111564.
- 652 Dragovic, G. (2013). Acute pancreatitis in HIV/AIDS patients: an issue of concern. *Asian Pac. J.*
653 *Trop. Biomed.* 3, 422–425. doi: 10.1016/S2221-1691(13)60091-X.
- 654 Du, W.-D., Yuan, Z.-R., Sun, J., Tang, J.-X., Cheng, A.-Q., Shen, D.-M., et al. (2003). Therapeutic
655 efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. *World J.*
656 *Gastroenterol.* 9, 2565–2569. doi: 10.3748/wjg.v9.i11.2565.
- 657 Du, X.-M., Kim, M.-J., Hou, L., Le Goff, W., Chapman, M. J., Van Eck, M., et al. (2015). HDL
658 Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol
659 Export. *Circ. Res.* 116, 1133–1142. doi: 10.1161/CIRCRESAHA.116.305485.
- 660 Elebo, N., Omoshoro-Jones, J., Fru, P. N., Devar, J., De Wet van Zyl, C., Vorster, B. C., et al.
661 (2021). Serum Metabolomic and Lipoprotein Profiling of Pancreatic Ductal Adenocarcinoma
662 Patients of African Ancestry. *Metabolites* 11, 663. doi: 10.3390/metabo11100663.
- 663 Eriksson, L., Jaworska, J., Worth, A. P., Cronin, M. T. D., McDowell, R. M., and Gramatica, P.
664 (2003). Methods for reliability and uncertainty assessment and for applicability evaluations
665 of classification- and regression-based QSARs. *Environ. Health Perspect.* 111, 1361–1375.
666 doi: 10.1289/ehp.5758.
- 667 Fonteh, P., Smith, M., and Brand, M. (2018). Adaptive Immune Cell Dysregulation and Role in
668 Acute Pancreatitis Disease Progression and Treatment. *Arch. Immunol. Ther. Exp.*
669 *(Warsz.)* 66, 199–209. doi: 10.1007/s00005-017-0495-1.
- 670 Forrest, L. M., McMillan, D. C., McArdle, C. S., Angerson, W. J., and Dunlop, D. J. (2003).
671 Evaluation of cumulative prognostic scores based on the systemic inflammatory response
672 in patients with inoperable non-small-cell lung cancer. *Br. J. Cancer* 89, 1028–1030. doi:
673 10.1038/sj.bjc.6601242.
- 674 Foster, B. R., Jensen, K. K., Bakis, G., Shaaban, A. M., and Coakley, F. V. (2016). Revised Atlanta
675 Classification for Acute Pancreatitis: A Pictorial Essay. *RadioGraphics*. doi:
676 10.1148/rg.2016150097.
- 677 Fratantoni, M. E., Giuffrida, P., Di Menno, J., Ardiles, V., de Santibañes, M., Clariá, R. S., et al.
678 (2021). Prevalence of Persistent Common Bile Duct Stones in Acute Biliary Pancreatitis
679 Remains Stable Within the First Week of Symptoms. *J. Gastrointest. Surg.* 25, 3178–3187.
680 doi: 10.1007/s11605-021-05068-0.
- 681 Funnell, I. C., Bornman, P. C., Weakley, S. P., Terblanche, J., and Marks, I. N. (1993). Obesity: An
682 important prognostic factor in acute pancreatitis. *BJS Br. J. Surg.* 80, 484–486. doi:
683 10.1002/bjs.1800800426.
- 684 Gao, L., Chong, E., Pendharkar, S., Phillips, A., Ke, L., Li, W., et al. (2021). The Challenges and

- 685 Effects of Ascorbic Acid Treatment of Acute Pancreatitis: A Systematic Review and Meta-
686 Analysis of Preclinical and Clinical Studies. *Front. Nutr.* 8. Available at:
687 <https://www.frontiersin.org/articles/10.3389/fnut.2021.734558> [Accessed October 5, 2023].
- 688 Garg, P. K., and Singh, V. P. (2019). Organ Failure Due to Systemic Injury in Acute Pancreatitis.
689 *Gastroenterology* 156, 2008–2023. doi: 10.1053/j.gastro.2018.12.041.
- 690 Gomatos, I. P., Xiaodong, X., Ghaneh, P., Halloran, C., Raraty, M., Lane, B., et al. (2014).
691 Prognostic markers in acute pancreatitis. *Expert Rev. Mol. Diagn.* 14, 333–46. doi:
692 10.1586/14737159.2014.897608.
- 693 Goodchild, G., Chouhan, M., and Johnson, G. J. (2019). Practical guide to the management of
694 acute pancreatitis. *Frontline Gastroenterol.* 10, 292–299. doi: 10.1136/flgastro-2018-
695 101102.
- 696 Gu, W., and Tong, Z. (2019). Clinical Application of Metabolomics in Pancreatic Diseases: A Mini-
697 Review. *Lab. Med.*, 116–121. doi: 10.1093/labmed/lmz046.
- 698 Güngör, B., Çağlayan, K., Polat, C., Şeren, D., Erzurumlu, K., and Malazgirt, Z. (2011). The
699 Predictivity of Serum Biochemical Markers in Acute Biliary Pancreatitis. *ISRN*
700 *Gastroenterol.* 2011, 1–5. doi: 10.5402/2011/279607.
- 701 Hofmeyr, S., Meyer, C., and Warren, B. L. (2014). Serum lipase should be the laboratory test of
702 choice for suspected acute pancreatitis. *S. Afr. J. Surg.* 52, 72–75.
- 703 Holmes, E., Wist, J., Masuda, R., Lodge, S., Nitschke, P., Kimhofer, T., et al. (2021). Incomplete
704 Systemic Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized
705 COVID-19 Patients: Implications for Assessment of Post-Acute COVID-19 Syndrome. *J.*
706 *Proteome Res.* 20, 3315–3329. doi: 10.1021/acs.jproteome.1c00224.
- 707 Hong, W., Geng, W., Chen, B., Basharat, Z., Wu, Q., Zimmer, V., et al. (2017). Predictors of acute
708 pancreatitis with low elevation of serum amylase. *Ther. Clin. Risk Manag.* 13, 1577–1584.
709 doi: 10.2147/TCRM.S147594.
- 710 Hoque, M. M., Shimizu, S., Juan, E. C. M., Sato, Y., Hossain, M. T., Yamamoto, T., et al. (2009).
711 Structure of d-3-hydroxybutyrate dehydrogenase prepared in the presence of the substrate
712 d-3-hydroxybutyrate and NAD⁺. *Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun.*
713 65, 331–335. doi: 10.1107/S1744309109008537.
- 714 Huang, J., He, D., Chen, L., Dong, C., Zhang, S., Qin, Y., et al. (2019). GC-MS based
715 metabolomics strategy to distinguish three types of acute pancreatitis. *Pancreatology* 19,
716 630–637. doi: 10.1016/j.pan.2019.05.456.
- 717 Huang, Y., Wen, Y., Wang, R., Hu, L., Yang, J., Yang, J., et al. (2022). Temporal metabolic
718 trajectory analyzed by LC-MS/MS based targeted metabolomics in acute pancreatitis
719 pathogenesis and Chaiqin Chengqi decoction therapy. *Phytomedicine* 99, 153996. doi:
720 10.1016/j.phymed.2022.153996.
- 721 Iannuzzi, J. P., King, J. A., Leong, J. H., Quan, J., Windsor, J. W., Tanyingoh, D., et al. (2022).
722 Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and
723 Meta-Analysis. *Gastroenterology* 162, 122–134. doi: 10.1053/j.gastro.2021.09.043.
- 724 Ismail, O. Z., and Bhayana, V. (2017). Lipase or amylase for the diagnosis of acute pancreatitis?
725 *Clin. Biochem.* 50, 1275–1280. doi: 10.1016/j.clinbiochem.2017.07.003.
- 726 Iyer, S., Bawa, E. P., Tarique, M., and Dudeja, V. (2020). Know Thy Enemy—Understanding the
727 Role of Inflammation in Severe Acute Pancreatitis. *Gastroenterology* 158, 46–48. doi:
728 10.1053/j.gastro.2019.11.039.

- 729 John, K. D., Segal, I., Hassan, H., Levy, R. D., and Amin, M. (1997). Acute pancreatitis in sowedan
730 africans. *Int. J. Pancreatol.* 21, 149–155. doi: 10.1007/BF02822386.
- 731 Jong, M. C., Hendriks, W. L., van Vark, L. C., Dahlmans, V. E. H., Groener, J. E. M., and Havekes,
732 L. M. (2000). Oxidized VLDL Induces Less Triglyceride Accumulation in J774 Macrophages
733 Than Native VLDL Due to an Impaired Extracellular Lipolysis. *Arterioscler. Thromb. Vasc.*
734 *Biol.* 20, 144–151. doi: 10.1161/01.ATV.20.1.144.
- 735 Karpińska, M., and Czauderna, M. (2022). Pancreas—Its Functions, Disorders, and Physiological
736 Impact on the Mammals' Organism. *Front. Physiol.* 13. Available at:
737 <https://www.frontiersin.org/articles/10.3389/fphys.2022.807632> [Accessed October 5,
738 2023].
- 739 Kay, P. S., Smith, M., and Br, M. (2017). The Initiating Immune Response of Acute Pancreatitis
740 May be Mediated by the T-Helper 17 Pathway. *J. Pancreas* 18, 0–0.
- 741 Ketavarapu, V., Ravikanth, V., Sasikala, M., Rao, G. V., Devi, Ch. V., Sripadi, P., et al. (2022).
742 Integration of metabolites from meta-analysis with transcriptome reveals enhanced SPHK1
743 in PDAC with a background of pancreatitis. *BMC Cancer* 22, 792. doi: 10.1186/s12885-
744 022-09816-6.
- 745 Khan, J., Nordback, I., and Sand, J. (2013). Serum Lipid Levels Are Associated with the Severity of
746 Acute Pancreatitis. *Digestion* 87, 223–228. doi: 10.1159/000348438.
- 747 Khatua, B., El-Kurdi, B., and Singh, V. P. (2017). Obesity and pancreatitis. *Curr. Opin.*
748 *Gastroenterol.* 33, 374–382. doi: 10.1097/MOG.0000000000000386.
- 749 Kotan, R., Peto, K., Deak, A., Szentkereszty, Z., and Nemeth, N. (2023). Hemorheological and
750 Microcirculatory Relations of Acute Pancreatitis. *Metabolites* 13, 4. doi:
751 10.3390/metabo13010004.
- 752 Lamiquiz-Moneo, Civeira, Gómez-Coronado, Blanco-Vaca, Villafuerte-Ledesma, Gil, et al. (2019).
753 Lipid Profile Rather Than the LCAT Mutation Explains Renal Disease in Familial LCAT
754 Deficiency. *J. Clin. Med.* 8, 1860. doi: 10.3390/jcm8111860.
- 755 Leppäniemi, A., Tolonen, M., Tarasconi, A., Segovia-Lohse, H., Gamberini, E., Kirkpatrick, A. W.,
756 et al. (2019). 2019 WSES guidelines for the management of severe acute pancreatitis.
757 *World J. Emerg. Surg.* 14, 27. doi: 10.1186/s13017-019-0247-0.
- 758 Li, J., Zhao, X., Liu, Y., Peng, X., Zhu, S., Guo, H., et al. (2014). 1HNMR-based metabolomic
759 profile of rats with experimental acute pancreatitis. *BMC Gastroenterol.* 14, 115. doi:
760 10.1186/1471-230X-14-115.
- 761 Lindon, J. C., and Nicholson, J. K. (2008). Analytical technologies for metabonomics and
762 metabolomics, and multi-omic information recovery. *TrAC Trends Anal. Chem.* 27, 194–
763 204. doi: 10.1016/j.trac.2007.08.009.
- 764 Lodge, S., Nitschke, P., Kimhofer, T., Wist, J., Bong, S.-H., Loo, R. L., et al. (2021). Diffusion and
765 Relaxation Edited Proton NMR Spectroscopy of Plasma Reveals a High-Fidelity
766 Supramolecular Biomarker Signature of SARS-CoV-2 Infection. *Anal. Chem.* 93, 3976–
767 3986. doi: 10.1021/acs.analchem.0c04952.
- 768 Luszczek, E. R., Paulo, J. A., Saltzman, J. R., Kadiyala, V., Banks, P. A., Beilman, G., et al. (2013).
769 Urinary 1H-NMR Metabolomics Can Distinguish Pancreatitis Patients from Healthy
770 Controls. *JOP J. Pancreas* 14, 161–170.
- 771 Magrini, L., Gagliano, G., Travaglino, F., Vetrone, F., Marino, R., Cardelli, P., et al. (2014).
772 Comparison between white blood cell count, procalcitonin and C reactive protein as

- 773 diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to
774 emergency department. *Clin. Chem. Lab. Med. CCLM* 52, 1465–1472. doi: 10.1515/ccm-
775 2014-0210.
- 776 Mallol, R., Amigó, N., Rodríguez, M. A., Heras, M., Vinaixa, M., Plana, N., et al. (2015). Liposcale:
777 a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy [S].
778 *J. Lipid Res.* 56, 737–746. doi: 10.1194/jlr.D050120.
- 779 Marshall, I., Higinbotham, J., Bruce, S., and Freise, A. (1997). Use of voigt lineshape for
780 quantification of in vivo 1H spectra. *Magn. Reson. Med.* 37, 651–657. doi:
781 10.1002/mrm.1910370504.
- 782 McDonald, O. G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S. J., Warmoes, M. O., et al.
783 (2017). Epigenomic reprogramming during pancreatic cancer progression links anabolic
784 glucose metabolism to distant metastasis. *Nat. Genet.* 49, 367–376. doi: 10.1038/ng.3753.
- 785 McGuire, L. C. (2006). Alcoholic ketoacidosis. *Emerg. Med. J.* 23, 417–420. doi:
786 10.1136/emj.2004.017590.
- 787 Moran, R. A., García-Rayado, G., de la Iglesia-García, D., Martínez-Moneo, E., Fort-Martorell, E.,
788 Lauret-Braña, E., et al. (2018). Influence of age, body mass index and comorbidity on major
789 outcomes in acute pancreatitis, a prospective nation-wide multicentre study. *United Eur.*
790 *Gastroenterol. J.* 6, 1508–1518. doi: 10.1177/2050640618798155.
- 791 Murphy, A. J., and Woollard, K. J. (2010). High-density lipoprotein: A potent inhibitor of
792 inflammation. *Clin. Exp. Pharmacol. Physiol.* 37, 710–718. doi: 10.1111/j.1440-
793 1681.2009.05338.x.
- 794 Nadhem, O., and Salh, O. (2017). Acute Pancreatitis: An Atypical Presentation. *Case Rep.*
795 *Gastroenterol.* 11, 359–363. doi: 10.1159/000475920.
- 796 Nalisa, M., Nweke, E. E., Smith, M. D., Omoshoro-Jones, J., Devar, J. W., Metzger, R., et al.
797 (2021). Chemokine receptor 8 expression may be linked to disease severity and elevated
798 interleukin 6 secretion in acute pancreatitis. *World J. Gastrointest. Pathophysiol.* 12, 115–
799 133. doi: 10.4291/wjgp.v12.i6.115.
- 800 National Health Laboratory Services 2019/20 Annual Report; National Health Amendment Bill:
801 rejection | PMG (n.d.). Available at: <https://pmg.org.za/committee-meeting/32510/>
802 [Accessed October 8, 2023].
- 803 Nesvaderani, M., Eslick, G. D., Vagg, D., Faraj, S., and Cox, M. R. (2015). Epidemiology, aetiology
804 and outcomes of acute pancreatitis: A retrospective cohort study. *Int. J. Surg.* 23, 68–74.
805 doi: 10.1016/j.ijsu.2015.07.701.
- 806 Niknam, R., Moradi, J., Jahanshahi, K. A., Mahmoudi, L., and Ejtehadi, F. (2020). Association
807 Between Metabolic Syndrome and Its Components with Severity of Acute Pancreatitis.
808 *Diabetes Metab. Syndr. Obes.* 13, 1289–1296. doi: 10.2147/DMSO.S249128.
- 809 Ocskay, K., Vinkó, Z., Németh, D., Szabó, L., Bajor, J., Gódi, S., et al. (2021). Hypoalbuminemia
810 affects one third of acute pancreatitis patients and is independently associated with severity
811 and mortality. *Sci. Rep.* 11, 24158. doi: 10.1038/s41598-021-03449-8.
- 812 Otvos, J. D., Shalurova, I., Wolak-Dinsmore, J., Connelly, M. A., Mackey, R. H., Stein, J. H., et al.
813 (2015). GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic
814 Inflammation. *Clin. Chem.* 61, 714–723. doi: 10.1373/clinchem.2014.232918.
- 815 Phatlhane, D. V., and Zemlin, A. E. (2016). Severe hypercholesterolemia mediated by lipoprotein X
816 in a patient with cholestasis. *Ann. Hepatol.* 14, 924–928.

- 817 Quinlan, J. D. (2014). Acute Pancreatitis. *Am. Fam. Physician* 90, 632–639.
- 818 Rakonczay, Z., Hegyi, P., Takacs, T., McCarroll, J., and Saluja, A. K. (2008). The role of NF-
819 [kappa]B activation in the pathogenesis of acute pancreatitis. *Gut* 57, 259. doi:
820 10.1136/gut.2007.124115.
- 821 Reynolds, A. P., Richards, G., de la Iglesia, B., and Rayward-Smith, V. J. (2006). Clustering Rules:
822 A Comparison of Partitioning and Hierarchical Clustering Algorithms. *J. Math. Model.*
823 *Algorithms* 5, 475–504. doi: 10.1007/s10852-005-9022-1.
- 824 Rousseeuw, P. J. (1987). Silhouettes: A graphical aid to the interpretation and validation of cluster
825 analysis. *J. Comput. Appl. Math.* 20, 53–65. doi: 10.1016/0377-0427(87)90125-7.
- 826 Sakai, A., Nishiumi, S., Shiomi, Y., Kobayashi, T., Izumi, Y., Kutsumi, H., et al. (2012).
827 Metabolomic analysis to discover candidate therapeutic agents against acute pancreatitis.
828 *Arch. Biochem. Biophys.* 522, 107–120. doi: 10.1016/j.abb.2012.03.025.
- 829 Sandstrom, P., Trulsson, L., Gasslander, T., Sundqvist, T., von Döbeln, U., and Svanvik, J. (2008).
830 Serum amino acid profile in patients with acute pancreatitis. *Amino Acids* 35, 225–231. doi:
831 10.1007/s00726-007-0557-5.
- 832 Serkova, N., Florian Fuller, T., Klawitter, J., Freise, C. E., and Niemann, C. U. (2005). 1H-NMR–
833 based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney
834 transplants. *Kidney Int.* 67, 1142–1151. doi: 10.1111/j.1523-1755.2005.00181.x.
- 835 Shah, I., Yakah, W., Ahmed, A., Freedman, S. D., Jiang, Z. G., and Sheth, S. G. (2023). GlycA:
836 Evaluation of a New Biomarker of Acute Pancreatitis. *Biomolecules* 13, 1530. doi:
837 10.3390/biom13101530.
- 838 Siddiqui, M. A., Pandey, S., Azim, A., Sinha, N., and Siddiqui, M. H. (2020). Metabolomics: An
839 emerging potential approach to decipher critical illnesses. *Biophys. Chem.* 267, 106462.
840 doi: 10.1016/j.bpc.2020.106462.
- 841 Silva, R. A., Pereira, T. C. S., Souza, A. R., and Ribeiro, P. R. (2020). 1H NMR-based metabolite
842 profiling for biomarker identification. *Clin. Chim. Acta* 502, 269–279. doi:
843 10.1016/j.cca.2019.11.015.
- 844 Silva-Vaz, P., Abrantes, A. M., Morgado-Nunes, S., Castelo-Branco, M., Gouveia, A., Botelho, M.
845 F., et al. (2020). Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis.
846 *Int. J. Mol. Sci.* 21, 4300. doi: 10.3390/ijms21124300.
- 847 Singh, A., Chen, M., Li, T., Yang, X.-L., Li, J.-Z., and Gong, J.-P. (2012). Parenteral Nutrition
848 Combined with Enteral Nutrition for Severe Acute Pancreatitis. *ISRN Gastroenterol.* 2012,
849 1–7. doi: 10.5402/2012/791383.
- 850 Soeters, P. B., Wolfe, R. R., and Shenkin, A. (2019). Hypoalbuminemia: Pathogenesis and Clinical
851 Significance. *J. Parenter. Enter. Nutr.* 43, 181–193. doi: 10.1002/jpen.1451.
- 852 Szatmary, P., Grammatikopoulos, T., Cai, W., Huang, W., Mukherjee, R., Halloran, C., et al.
853 (2022). Acute Pancreatitis: Diagnosis and Treatment. *Drugs* 82, 1251–1276. doi:
854 10.1007/s40265-022-01766-4.
- 855 Szymańska, E., Saccenti, E., Smilde, A. K., and Westerhuis, J. A. (2012). Double-check: validation
856 of diagnostic statistics for PLS-DA models in metabolomics studies. *Metabolomics* 8, 3–16.
857 doi: 10.1007/s11306-011-0330-3.
- 858 Thiyagarajan, U. M., and Amirthavarshini Ponnuswamy, R. T. (2020). Predictivity of Biochemical
859 Markers on Aetiology and Length of Hospitalisation in Acute Pancreatitis.

- 860 Thomson, J.-E., Brand, M., and Fonteh, P. (2018). The immune imbalance in the second hit of
861 pancreatitis is independent of IL-17A. *Pancreatology* 18, 246–252. doi:
862 10.1016/j.pan.2018.01.007.
- 863 Thomson, J.-E., Nweke, E. E., Brand, M., Nel, M., Candy, G. P., and Fonteh, P. N. (2019).
864 Transient expression of Interleukin-21 in the second hit of acute pancreatitis may potentiate
865 immune paresis in severe acute pancreatitis. doi: 10.1097/MPA.0000000000001207.
- 866 Treacy, J., Williams, A., Bais, R., Willson, K., Worthley, C., Reece, J., et al. (2001). Evaluation of
867 amylase and lipase in the diagnosis of acute pancreatitis. *ANZ J. Surg.* 71, 577–582. doi:
868 10.1046/j.1445-2197.2001.02220.x.
- 869 Valverde-López, F., Matas-Cobos, A. M., Alegría-Motte, C., Jiménez-Rosales, R., Úbeda-Muñoz,
870 M., and Redondo-Cerezo, E. (2017). BISAP, RANSON, lactate and others biomarkers in
871 prediction of severe acute pancreatitis in a European cohort. *J. Gastroenterol. Hepatol.* 32,
872 1649–1656. doi: 10.1111/jgh.13763.
- 873 Villaseñor, A., Kinross, J. M., Li, J. V., Penney, N., Barton, R. H., Nicholson, J. K., et al. (2014). 1H
874 NMR Global Metabolic Phenotyping of Acute Pancreatitis in the Emergency Unit. *J.*
875 *Proteome Res.* 13, 5362–5375. doi: 10.1021/pr500161w.
- 876 Xiao, H., Huang, J., Zhang, X., Ahmed, R., Xie, Q., Li, B., et al. (2017). Identification of potential
877 diagnostic biomarkers of acute pancreatitis by serum metabolomic profiles. *Pancreatology*
878 17, 543–549. doi: 10.1016/j.pan.2017.04.015.
- 879 Xiao, W., Liu, W., Yin, L., Li, Y., Lu, G., Liu, X., et al. (2020). Serum hydroxybutyrate
880 dehydrogenase as an early predictive marker of the severity of acute pancreatitis: a
881 retrospective study. *BMC Gastroenterol.* 20, 393. doi: 10.1186/s12876-020-01521-7.
- 882 Xu, H., Zhang, L., Kang, H., Zhang, J., Liu, J., and Liu, S. (2016). Serum Metabonomics of Mild
883 Acute Pancreatitis. *J. Clin. Lab. Anal.* 30, 990–998. doi: 10.1002/jcla.21969.
- 884 Xu, J., Pan, T., Qi, X., Tan, R., Wang, X., Liu, Z., et al. (2020). Increased mortality of acute
885 respiratory distress syndrome was associated with high levels of plasma phenylalanine.
886 *Respir. Res.* 21, 99. doi: 10.1186/s12931-020-01364-6.
- 887 Yadav, D., and Lowenfels, A. B. (2013). The Epidemiology of Pancreatitis and Pancreatic Cancer.
888 *Gastroenterology* 144, 1252–1261. doi: 10.1053/j.gastro.2013.01.068.
- 889 Yang, A. L. (2008). Epidemiology of Alcohol-Related Liver and Pancreatic Disease in the United
890 States. *Arch. Intern. Med.* 168, 649. doi: 10.1001/archinte.168.6.649.
- 891 Yang, A. L., and McNabb-Baltar, J. (2020). Hypertriglyceridemia and acute pancreatitis.
892 *Pancreatology* 20, 795–800. doi: 10.1016/j.pan.2020.06.005.
- 893 Yuksekdog, S., Yuksel, E., Topcu, A., Karaagac, N., Uzun, H., Kiziler, A. R., et al. (2019). Serum
894 paraoxonase (a high-density lipoprotein-associated lipophilic antioxidant) activity in clinical
895 follow-up of patients with acute pancreatitis, with particular emphasis on oxidative stress
896 parameters and lipid profile: a prospective pilot trial. *Libyan J. Med.* 14, 1595955. doi:
897 10.1080/19932820.2019.1595955.
- 898 Zhang, Y., Guo, F., Li, S., Wang, F., Meng, Z., Zhao, J., et al. (2017). Decreased high density
899 lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic
900 necrosis and mortality in acute pancreatitis. *Sci. Rep.* 7, 8064. doi: 10.1038/s41598-017-
901 06618-w.
- 902 Zheng, L., Xue, J., Jaffee, E. M., and Habtezion, A. (2013). Role of Immune Cells and Immune-
903 Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma. *Gastroenterology*

904 144, 1230–1240. doi: 10.1053/j.gastro.2012.12.042.

905 Zilio, M. B., Eyff, T. F., Azeredo-Da-Silva, A. L. F., Bersch, V. P., and Osvaldt, A. B. (2019). A
906 systematic review and meta-analysis of the aetiology of acute pancreatitis. *HPB* 21, 259–
907 267. doi: 10.1016/j.hpb.2018.08.003.

908